{"name":"Innostellar Biotherapeutics Co.,Ltd","slug":"innostellar-biotherapeutics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aflibercept intravitreal injection","genericName":"Aflibercept intravitreal injection","slug":"aflibercept-intravitreal-injection","indication":"Neovascular (wet) age-related macular degeneration","status":"phase_2"}]}],"pipeline":[{"name":"Aflibercept intravitreal injection","genericName":"Aflibercept intravitreal injection","slug":"aflibercept-intravitreal-injection","phase":"phase_2","mechanism":"Aflibercept binds to vascular endothelial growth factors (VEGFs) and placental growth factor (PlGF), preventing their interaction with VEGF receptors and thus inhibiting angiogenesis and vascular permeability.","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNNzg2TG1VWW1CdXdkQUFuUzRVd0JGQ0x0OEMyQ2p6OWh1QjRnXy1fUXQzTFJyRkpWdEVaZ0t6R21qelJjVEpjRzdTMnU1S0M4dVphZ1o1aGhiVEx6ams2QjFVQ1ROSkV0RkwtU1c0SjVDZUJoZ1JLczFveEhXekxHOGtadF9IR193bVhMVFhiSThlNk9TaFl2TVYzcVA1ajFMbjFqbDRmTkJnMXVKUmh0YldiZVh6QkVWSnM3QUpCTmhYdEh3c3RMS2NlOWo4NzNQMkhaVmp6Q0Vmdnp6OUNsT2hONWh4ek5ZZDRIdWFXeDJKbm5kbjlNY05lMnhyTzRGRkRaeXlFZFM4MUtVbmg1M1BKWFc?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"AAV Vectors in Gene Therapy Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"AAV Vectors in Gene Therapy Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-05","type":"trial","source":"GlobeNewswire","summary":"AAV for the Hereditary Retinal Diseases Clinical Trial - GlobeNewswire","headline":"AAV for the Hereditary Retinal Diseases Clinical Trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}